NCR3 and breast cancer: NKp30 CAR TCRKO T cells and their TCR+ counterparts, generated from either BC 1 or BC 2 and used on d25 of expansion (see Figure 3B), were co-cultured with FLuc expressing tumor target cell lines HL-60, K562, HEK 293, and A375 for 20 h followed by measuring residual luciferase activity.